Brief: Cspc Pharmaceutical Announces Exclusive License Agreement With Jiangsu Alphamab
Aug 23 (Reuters) - CSPC Pharmaceutical Group Ltd 1093.HK :
* EXCLUSIVE LICENSE AGREEMENT WITH JIANGSU ALPHAMAB FOR
DEVELOPMENT AND COMMERCIALIZATION OF KN026 IN CHINA
* UNIT TO PAY AN UPFRONT PAYMENT OF RMB150 MILLION &
DEVELOPMENT
MILESTONE PAYMENTS OF UP TO RMB450 MILLION FOR DEAL
Further company coverage: 1093.HK
Recent news on Alphamab Oncology
See all newsBrief: Alphamab Oncology Says Fei Wang Resigns As Chief Financial Officer
Brief: Alphamab Oncology Says First Patient Dosed In Phase III Clinical Study Of JSKN033 Monotherapy For Treatment Of Cervical Cancer
Brief: Alphamab Oncology Says Board Resolves To Repurchase Shares Up To HK$80 Million In Value
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab With HB1801 For Her2+ Advanced Breast Cancer
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab (KN026)